Abingworth LLP purchased a new position in GTx, Inc. (NASDAQ:GTXI) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 339,174 shares of the biopharmaceutical company’s stock, valued at approximately $2,781,000. GTX accounts for approximately 1.9% of Abingworth LLP’s investment portfolio, making the stock its 11th biggest position. Abingworth LLP owned about 2.11% of GTX as of its most recent SEC filing.

Separately, Bank of New York Mellon Corp acquired a new position in shares of GTX during the second quarter valued at about $124,000. 11.57% of the stock is owned by hedge funds and other institutional investors.

GTx, Inc. (GTXI) opened at $12.39 on Wednesday. GTx, Inc. has a twelve month low of $2.73 and a twelve month high of $13.35.

GTX (NASDAQ:GTXI) last released its quarterly earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.25). research analysts forecast that GTx, Inc. will post -1.61 earnings per share for the current year.

GTXI has been the subject of a number of analyst reports. Stifel Nicolaus initiated coverage on shares of GTX in a report on Thursday, November 9th. They set a “buy” rating for the company. Robert W. Baird initiated coverage on shares of GTX in a report on Tuesday, November 21st. They set an “outperform” rating and a $17.00 price objective for the company.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://theolympiareport.com/2017/12/06/abingworth-llp-takes-position-in-gtx-inc-gtxi.html.

GTX Profile

GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).

Receive News & Ratings for GTx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTx Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.